Prawo i regulacje · 31/01/2020

US FDA Approves Lasmiditan for Oral Use, DEA Places in Schedule V

The US FDA approved lasmiditan, a new oral medication, on October 11, 2019, and the DEA subsequently placed it in Schedule V of the Controlled Substances Act, following a recommendation from the Department of Health and Human Services.